NCT02578277

Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates

Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: ViiV Healthcare · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to study the effects of BMS-955176 on the single-dose PK parameters of probe substrates caffeine, metoprolol, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin

Conditions

• HIV Infections

Interventions

Type	Name	Description
DRUG	CYP and transporter probe substrates	Cocktail of CYP (cytochrome P450) and transporter probe substrates
DRUG	BMS-955176	BMS-955176
DRUG	BMS-955176 plus CYP and transporter probe substrates	BMS-955176 plus the cocktail of CYP and transporter probe substrates

Timeline

• Start date: 2015-11-09
• Primary completion: 2015-12-23
• Completion: 2015-12-23
• First posted: 2015-10-16
• Last updated: 2018-07-13

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study